| The question CEA answers | The question it does not |
|---|---|
| Which of these does more good per rupee? | Is this programme worth doing at all? |
| What does the upgrade cost per extra unit? | Who should receive it? |
| Where would the next rupee do most? | Whether the outcome is the right one to want |
| Decision | The visible cost | The opportunity cost |
|---|---|---|
| Fund a tertiary cardiac unit | The capital and running budget | The immunisation rounds not run |
| Extend a pilot in one district | The extension budget | A different district that gets nothing |
| Hire an M&E specialist | One salary | Two field staff |
| Do nothing while deciding | Zero on the ledger | A year of outcomes forgone |
| Step | The question at that step |
|---|---|
| A fixed budget | What can we actually spend? |
| Competing worthy options | What are the real alternatives, including current practice? |
| Evidence on cost per outcome | Estimated how, from where, with what uncertainty? |
| Allocation | Who gains and who loses if we shift? |
| Programme A | Programme B | |
|---|---|---|
| Cost per case averted | ₹5,000 | ₹500 |
| Cases averted for ₹10 lakh | 200 | 2,000 |
| Both are genuinely effective? | Yes | Yes |
| Programme | Cost | Outcomes | Cost per outcome |
|---|---|---|---|
| Cheapest | ₹1 lakh | 5 | ₹20,000 |
| Mid | ₹5 lakh | 100 | ₹5,000 |
| Most expensive | ₹20 lakh | 800 | ₹2,500 |
| Who uses it | For what decision |
|---|---|
| Health ministries | Which treatments a public scheme covers |
| India’s HTA agency | Advice on technologies and their prices |
| Funders and grant committees | Allocating across strong applicants |
| NGOs | Choosing between designs for one goal |
| WHO, World Bank, DCP3 | Ranking interventions across diseases |
| CEA supplies | The decision also needs |
|---|---|
| Cost per unit of outcome | Whether that outcome is the right goal |
| A ranking of options | Who each option reaches |
| A defensible efficiency case | Rights, obligations and law |
| A basis for reallocation | Whether reallocation is politically possible |
| South Asian condition | Consequence for allocation |
|---|---|
| Low public health spending per head | Every rupee displaces another rupee of care |
| High disease and deprivation burden | Many interventions are competitive on paper |
| High out-of-pocket share of health spending | Participant costs dominate and are rarely counted |
| Wide district-level variation | A national average ratio fits almost nowhere |
| Method | Denominator | Comparison scope | Main hazard |
|---|---|---|---|
| CEA | Natural units | Same outcome only | Cannot compare across outcomes |
| CUA | DALYs / QALYs | Across health | Weights embed contested values |
| CBA | Money | Across sectors | Requires pricing health and life |
| CEA works when | It breaks when |
|---|---|
| All options share one outcome | Options produce different kinds of good |
| The outcome is well defined | The unit shifts — "case detected" vs "case cured" |
| The outcome is what you care about | It is a convenient proxy for something else |
| You are choosing within a sector | You must choose between sectors |
| CBA requires pricing | Method used | Objection |
|---|---|---|
| A statistical life | Willingness-to-pay or wage-risk studies | Values scale with income, so poorer lives price lower |
| A year of schooling | Later earnings | Reduces education to labour-market return |
| Environmental damage | Stated preference surveys | Hypothetical answers to hypothetical prices |
| Method | Benefit measured in | Lets you compare |
|---|---|---|
| CEA | Natural units (cases, children, years) | Programmes with the same outcome |
| CUA | DALYs or QALYs | Any health programmes, across diseases |
| CBA | Money (₹) | Anything — health, roads, schools |
| CMA* | (costs only; outcomes assumed equal) | Options with identical effect |
| You need to compare | Use |
|---|---|
| Three designs for raising immunisation coverage | CEA — shared natural outcome |
| A blindness programme against a diarrhoea programme | CUA — DALYs bridge them |
| A rural road against a district hospital | CBA — only money spans sectors |
| Two suppliers of an identical product | Cost-minimisation — effects are equal by assumption |
| Your comparison | Method | What you must then supply |
|---|---|---|
| Designs for one outcome | CEA | One clearly defined natural unit |
| Across health conditions | CUA | Disability or utility weights, and a threshold |
| Across sectors | CBA | Money values for non-market benefits |
| Identical effects | Cost-minimisation | Evidence that the effects really are identical |
| Never compare | Because |
|---|---|
| A CEA ratio against a CBA ratio | Different denominators; the units are not commensurable |
| Provider-perspective against societal-perspective costs | One counts participant costs, the other does not |
| Ratios using different discount rates | The rate alone can change the ranking |
| An average CER against an ICER | They answer different questions |
| Cost routinely omitted | Effect on the ratio |
|---|---|
| Head-office overheads | Understates cost; flatters the programme |
| Volunteer and community time | Hides the true resource use, often substantial |
| Donated goods and seconded staff | Makes a subsidised model look replicable |
| Participants’ time, fares and lost wages | Ignores the largest cost for the poorest |
| Capital already owned | Treats an existing building as free |
| Ingredient | Priced at |
|---|---|
| Staff time | Salary plus benefits, apportioned by time actually spent |
| Donated goods | Market price — not zero |
| Volunteer time | The wage they forgo, or a local unskilled rate |
| A building already owned | Rental equivalent, or annualised capital cost |
| A vehicle | Annualised over its useful life, plus running costs |
| Apportioning indirect cost | Basis | Distorts when |
|---|---|---|
| By share of direct cost | Simplest | One programme is capital-heavy |
| By staff headcount | Fair for people-heavy support | Programmes differ in staff intensity |
| By beneficiary numbers | Intuitive | Reach varies in effort per person |
| Not at all | Common | Always — it understates cost |
| Fixed | Variable | |
|---|---|---|
| Examples | Training centre, vehicle, management team | Vaccines, stipends, per-child materials |
| With scale | Spread thinner per beneficiary | Rise roughly in proportion |
| At pilot size | Dominate; ratio looks bad | Small share |
| At scale | Small share | Dominate; ratio flattens out |
| Perspective | Counts costs to… | Often misses |
|---|---|---|
| Provider | The implementing organisation | Costs borne by participants |
| Participant | The beneficiary — travel, time, fees | Provider overheads |
| Societal | Everyone affected — the fullest view | Hardest to measure fully |
| Perspective | Counts | Typically omits |
|---|---|---|
| Provider | What the implementer spends | Everything borne by participants |
| Participant | Travel, fees, time, lost wages | Provider overheads |
| Health system | All public-sector costs | Household and private costs |
| Societal | All costs to anyone | Nothing — but is hardest to measure |
| Participant cost | Typical size |
|---|---|
| Lost wages for a day | Often the largest single item for a daily-wage worker |
| Transport to the facility | Doubles for an accompanying family member |
| Childcare, or children brought along | Rarely counted, always borne |
| Informal payments | Real, undocumented, and regressive |
| Cost line | Frequently excluded? |
|---|---|
| Direct delivery — staff, materials | No |
| Head-office overheads | Very often |
| Participant time and travel | Almost always |
| Capital, annualised | Often |
| Getting the denominator wrong | What happens |
|---|---|
| Counting outputs instead of outcomes | Cheap per unit, worthless per rupee |
| Counting reach instead of change | Rewards breadth over depth |
| Using a proxy nobody validated | A ratio precise about the wrong thing |
| Counting only outcomes you can measure | The programme optimises towards measurability |
| Sector | A defensible natural unit | A weak one |
|---|---|---|
| Health | Cases averted, deaths prevented | People screened |
| Education | Additional years of schooling; learning gains | Children enrolled |
| Nutrition | Children moved out of stunting | Supplements distributed |
| WASH | People with sustained safe-water access | Taps installed |
| Outcome level | Example | Measurable? | Meaningful? |
|---|---|---|---|
| Output | Nets distributed | Easily | Only if used |
| Intermediate | Nets used nightly | With effort | Closer |
| Final | Malaria cases averted | Hard | Yes |
| Ultimate | Deaths prevented, income raised | Hardest | Yes |
| Cost per… | Cheap to measure? | Can mislead because |
|---|---|---|
| Net distributed | Yes | An unused net averts nothing |
| Net used nightly | Harder | Usage may not be sustained |
| Case averted | Hard | Needs a counterfactual |
| Death prevented | Hardest | Rare events; large samples needed |
| Effect estimate | Counterfactual | Risk |
|---|---|---|
| Before-and-after change | None — assumes nothing else changed | Credits the programme with the trend |
| Comparison with non-participants | Weak — they differ by selection | Selection bias, usually upward |
| Quasi-experimental | Plausible, assumption-dependent | Fails if the assumption fails |
| RCT | Strong | May not transfer to your setting |
| Element | Value | What to check |
|---|---|---|
| Total cost | ₹6,00,000 | Perspective; overheads; participant time |
| Effect | 300 cases averted | Against what counterfactual? |
| Cost per outcome | ₹2,000 | Average or incremental? |
| Comparator | Unstated | This is the missing piece |
| Source | Strength | Caution |
|---|---|---|
| RCT / trial | Strong causal estimate | May not transfer to your context |
| Quasi-experiment | Real-world, plausible counterfactual | Assumptions can fail |
| Programme monitoring | Cheap, available | No counterfactual |
| Published meta-analysis | Pools many studies | Settings differ from yours |
| Source | Use it when | Adjust for |
|---|---|---|
| Your own RCT | It exists — rare | Nothing; this is the best case |
| RCT from elsewhere | Context is broadly similar | Baseline burden, prices, delivery quality |
| Quasi-experiment | No trial is feasible | State and test the identifying assumption |
| Meta-analysis | Several studies exist | Heterogeneity; the pooled estimate may fit nobody |
| Monitoring data | Only for costs, not effects | It has no counterfactual |
| Denominator chosen | Cost per unit | What it means |
|---|---|---|
| Leaflets printed | Very low | Almost nothing |
| People trained | Low | Attendance, not change |
| Practice changed | Higher | The intended outcome |
| Health outcome improved | Highest | The thing worth buying |
| CER tells you | It assumes |
|---|---|
| The average cost of one unit of outcome | That units are interchangeable |
| A basis for comparison | That other entries were built the same way |
| Whether a programme is worth running | That the comparator is doing nothing |
| Nothing about the next unit | Constant returns — usually false |
| Average CER | ICER | |
|---|---|---|
| Compares against | Doing nothing | The next-best option |
| Answers | What did the whole programme cost per unit? | What does the upgrade cost per extra unit? |
| Right for | Whether to run a programme at all | Choosing between options |
| Misused as | Justification for an upgrade | Rarely misused — more often absent |
| ICER component | What to get right |
|---|---|
| Cost A − Cost B | Both costed on the same perspective and horizon |
| Effect A − Effect B | Both effects from comparable evidence |
| The comparator B | Current practice, not "nothing" |
| The threshold | Stated, justified, and varied in sensitivity analysis |
| Cost | Effect | Average CER | ICER vs previous | |
|---|---|---|---|---|
| Do nothing | 0 | 0 | — | — |
| Option B | ₹5,00,000 | 200 | ₹2,500 | ₹2,500 |
| Option A | ₹8,00,000 | 260 | ₹3,077 | ₹5,000 |
| Strategy | Cost | Cases detected |
|---|---|---|
| B: standard screening | ₹5,00,000 | 200 |
| A: enhanced screening | ₹8,00,000 | 260 |
| Difference (A − B) | ₹3,00,000 | 60 extra |
| Question the funder should then ask | Why |
|---|---|
| Is an extra detected case worth ₹5,000? | This is the threshold question |
| Detected, or treated and cured? | Detection without treatment averts nothing |
| Who are the extra 60 cases? | Enhanced screening may reach a different group |
| Does the ₹5,000 hold at scale? | Marginal cost usually rises |
| Threshold basis | Problem with it |
|---|---|
| 1–3× GDP per capita | Arbitrary; unrelated to what the budget can afford |
| What was funded last year | Entrenches historical choices |
| A published benchmark from elsewhere | Reflects another country’s budget and burden |
| Opportunity cost of the actual budget | Correct in principle, demanding to estimate |
| Option | Cost | Effect | Verdict |
|---|---|---|---|
| Costs less, does more | Lower | Higher | Dominant — adopt, no ICER needed |
| Costs more, does less | Higher | Lower | Dominated — drop from the comparison |
| Costs more, does more | Higher | Higher | Compute the ICER; judge against a threshold |
| Costs less, does less | Lower | Lower | ICER of the downgrade — a savings question |
| Situation | Correct number |
|---|---|
| Should we run this programme at all? | Average CER against the status quo |
| Should we upgrade from B to A? | ICER of A versus B |
| Which of five options? | Rank by cost, drop dominated, ICERs along the frontier |
| Is this a good buy in general? | No single number answers this |
| Comparison | Possible with |
|---|---|
| Two malaria programmes | CEA — shared unit |
| Blindness prevention vs child mortality | CUA only |
| A treatment that extends life vs one that improves it | CUA — DALYs combine both |
| Health vs a rural road | CBA only |
| QALY | DALY | |
|---|---|---|
| Counts | Health gained | Health lost |
| Direction | Higher is better | Lower is better |
| Weights | Utility, 1 = full health, 0 = death | Disability, 0 = full health, 1 = death |
| Used mostly by | HTA agencies — NICE and similar | Global burden of disease work, WHO |
| Component | Calculation | Sensitive to |
|---|---|---|
| YLL | Reference life expectancy − age at death | Which reference life table is used |
| YLD | Years with the condition × disability weight | The weight, and duration estimates |
| DALY | YLL + YLD | Both, plus any age-weighting or discounting |
| Component | What it measures | Driven by |
|---|---|---|
| YLL | Years lost to premature death | Age at death against a reference life expectancy |
| YLD | Years lived in ill health | Duration × disability weight |
| Disability weight questions | Why it is contested |
|---|---|
| Whose judgements? | General-public surveys, not people with the condition |
| Do people with a condition agree? | Often not — they rate their own state higher |
| Is a year with disability worth less? | Disability-rights scholars argue the premise is wrong |
| Are they culturally stable? | Weights vary between populations surveyed |
| To compute cost per DALY averted, you need | Usually the weak link |
|---|---|
| Full programme cost | Overheads and participant costs |
| Cases averted, causally attributed | The counterfactual |
| DALYs per case | Disability weights and duration |
| A time horizon and discount rate | Both frequently unstated |
| Commonly cited as low cost per DALY | Caveat |
|---|---|
| Childhood vaccination | Depends on existing delivery infrastructure |
| Insecticide-treated bed nets | Depends on local malaria burden |
| Vitamin A supplementation | Effect size debated in recent trials |
| Threshold claim | Status |
|---|---|
| "Below 1× GDP per capita = highly cost-effective" | A rule of thumb, never an empirical finding |
| "Below 3× GDP per capita = cost-effective" | The same; widely used and widely criticised |
| "WHO recommends these thresholds" | No longer — WHO moved away from blanket multiples |
| "The threshold reflects what we can afford" | Only if derived from the actual budget constraint |
| Flow | Year 0 | Year 10 | Discounted at 3% |
|---|---|---|---|
| ₹1,00,000 cost | ₹1,00,000 | — | ₹1,00,000 |
| ₹1,00,000 benefit | — | ₹1,00,000 | About ₹74,400 |
| Reason to discount | Applies to money? | Applies to health? |
|---|---|---|
| Time preference | Yes | Contested |
| Opportunity cost of capital | Yes | Not directly |
| Uncertainty about the future | Yes | Yes |
| Inflation | No — handle separately in real terms | No |
| Symbol | Meaning | Where mistakes happen |
|---|---|---|
| r | Discount rate per year | Real, not nominal |
| t | Years from the present | Mid-year vs end-year conventions |
| PV | Present value | Must be applied to costs and benefits alike |
| ₹1,000 received in | Worth today at 3% | At 8% |
|---|---|---|
| Year 10 | About ₹744 | About ₹463 |
| Year 20 | About ₹554 | About ₹215 |
| Year 30 | About ₹412 | About ₹99 |
| Rate | Effect | Typically favours |
|---|---|---|
| 0% | Future counts equally | Prevention, children, climate |
| 3% | Common convention in health | Balanced |
| 8–12% | Future nearly vanishes | Immediate treatment over prevention |
| Position | Argument | Problem |
|---|---|---|
| Discount health at the same rate as money | Consistency; avoids paradoxes | Devalues future lives |
| Discount health at a lower rate | Health cannot be invested | Can justify indefinite delay |
| Do not discount health | All lives count equally | Postponing every programme looks costless |
| Horizon | Systematically favours | Systematically penalises |
|---|---|---|
| 3 years (a project cycle) | Treatment, immediate delivery | Prevention, education, infrastructure |
| 10 years | Most health programmes | Long-latency benefits |
| Lifetime | Prevention and early-childhood work | Nothing — but forecasts get shakier |
| Report | Because |
|---|---|
| The base-case rate | A reader cannot interpret the result without it |
| Why that rate | Convention, guideline, or funder requirement |
| Results at alternative rates | Shows whether the conclusion is rate-dependent |
| The time horizon alongside it | Rate and horizon interact strongly |
| For a comparison to be valid, all entries share | Or else |
|---|---|
| The same method | Denominators are not commensurable |
| The same perspective | Some entries count participant cost, others do not |
| The same discount rate and horizon | Long-payoff options are penalised inconsistently |
| Comparable outcome definitions | "Case detected" and "case cured" are not the same unit |
| Comparable contexts, or stated adjustment | You are comparing settings, not interventions |
| League table question | What to check |
|---|---|
| Who built it, and for what decision? | The framing shapes what was included |
| Were entries estimated the same way? | Method, perspective, horizon, rate |
| What is the uncertainty on each? | Overlapping ranges make the order meaningless |
| What is missing from the table? | Unmeasured outcomes count as zero |
| Trustworthy when | Check |
|---|---|
| Uncertainty shown per entry | Overlapping ranges make the order meaningless |
| Before reallocating, ask | Because |
|---|---|
| Do they serve the same people? | Efficiency gains can come from dropping the hardest to reach |
| Can the efficient one absorb the money? | Absorptive capacity is a real constraint |
| Does the ratio hold at larger scale? | Marginal cost rises as the easy cases are used up |
| What is lost when the other closes? | Staff, trust and reach are not instantly rebuilt |
| Stage of the deworming debate | What it established |
|---|---|
| Original trial and follow-ups | Large long-run schooling and earnings effects claimed |
| Replication and re-analysis | Coding and analytic choices materially changed results |
| Cochrane-style reviews | Little consistent effect on nutrition, haemoglobin or school performance |
| Current position | Genuinely contested; cheap enough that some still recommend it |
| Lesson from deworming | What to do about it |
|---|---|
| A ranking is only as solid as its effect estimate | Report the evidence grade beside the ratio |
| One influential study can move millions | Wait for replication before large reallocation |
| A cheap numerator cannot rescue an uncertain denominator | Sensitivity-test the effect, not just the cost |
| Precise ratios hide wide uncertainty | Publish the range, not the point |
| What differs across settings | Effect on a borrowed ratio |
|---|---|
| Baseline disease burden | Fewer cases to avert → worse ratio |
| Wage levels | Staff-intensive programmes cost differently |
| Existing delivery infrastructure | Marginal cost is far lower where a system exists |
| Programme quality at scale | Trial-quality delivery rarely survives scale-up |
| Coverage reached | Who remains | Marginal cost |
|---|---|---|
| First 50% | Accessible, willing, near a facility | Low |
| Next 30% | Further away, harder to persuade | Rising |
| Last 20% | Remote, mistrustful, hardest to serve | Often several times the average |
| Practice | Prevents |
|---|---|
| Same method, units, perspective, rate for all entries | Comparing incommensurable numbers |
| Show uncertainty per entry | A spurious ordering |
| State each estimate’s context | Transferring a ratio that does not hold |
| Pair the ranking with equity data | Efficiency achieved by not reaching the hardest |
| Report what could not be quantified | Unmeasured benefits valued at zero |
| Uncertain input | Typical range | Usually the biggest driver? |
|---|---|---|
| Effect size | Wide — from the confidence interval | Yes, almost always |
| Unit costs | Moderate | Sometimes |
| Discount rate | A stated set of alternatives | Yes, for long horizons |
| Coverage achieved | Wide at scale-up | Often |
| Vary | Plausible range from | If the decision flips |
|---|---|---|
| Effect size | The confidence interval | Buy better effect evidence before deciding |
| Unit costs | Observed variation across sites | Cost the specific setting properly |
| Coverage achieved | Pilot versus realistic scale-up | The scale-up assumption is the decision |
| Discount rate | 0%, base case, higher | Say the conclusion is rate-dependent |
| Tornado bar | Reading it |
|---|---|
| Widest bar at the top | The input that drives the answer |
| Bar crossing the threshold line | That input alone can flip the decision |
| All bars narrow | The conclusion is robust — report that |
| One-way | Probabilistic (PSA) | |
|---|---|---|
| Varies | One input at a time | All inputs together, from distributions |
| Output | A range per input; a tornado diagram | A distribution of results |
| Answers | Which input matters most? | What is the probability this is good value? |
| Effort | A spreadsheet | A simulation, thousands of runs |
| Quadrant | Cost | Effect | Decision |
|---|---|---|---|
| Lower right | Less | More | Dominant — adopt |
| Upper left | More | Less | Dominated — reject |
| Upper right | More | More | Depends on the threshold |
| Lower left | Less | Less | A savings trade-off — depends on the threshold |
| PSA cloud shape | Interpretation |
|---|---|
| Tight cluster below the threshold line | Confident good value |
| Wide cloud straddling the line | Genuinely uncertain — report the probability |
| Cloud spanning quadrants | Even the direction of effect is unclear |
| Intervention X | Intervention Y | |
|---|---|---|
| Point estimate | ₹5,000 per outcome | ₹5,000 per outcome |
| Plausible range | ₹4,500–5,500 | ₹900–40,000 |
| Probability below a ₹10,000 threshold | Near certain | Roughly a coin toss |
| Value | Can CEA weigh it? |
|---|---|
| Efficiency — outcomes per rupee | Yes — this is what it measures |
| Fairness in who receives | Only if you add equity weights |
| Rights and legal obligation | No — obligations do not depend on ratios |
| Dignity in how people are treated | No — process is invisible to the ratio |
| Political feasibility | No |
| Blind spot | Concrete example |
|---|---|
| Distribution | A total of outcomes achieved entirely in accessible districts |
| Rights and dignity | Emergency care owed regardless of the ratio |
| Process | Two programmes, same outcome, one treats people badly |
| The hard to reach | Higher cost per outcome; systematically deprioritised |
| Group | Cost per outcome | Need |
|---|---|---|
| Accessible urban households | Lowest | Lower |
| Rural, road-connected | Moderate | Moderate |
| Remote Adivasi hamlets | Highest | Highest |
| People with disabilities | Highest | Highest |
| Equity weighting decision | What it requires you to state |
|---|---|
| Who counts as worse-off | Income, caste, disability, geography — on what basis |
| How much extra weight | A number, chosen and defended |
| Whose judgement sets it | A committee, a public process, or an analyst alone |
| Sensitivity to the weight | Whether the ranking survives a different weight |
| Technical choice | The value it encodes |
|---|---|
| Disability weights | Whose view of a life worth living |
| Discount rate | How much future people count |
| Threshold | What a year of health is worth |
| Choice of outcome | What was worth counting at all |
| Perspective | Whose costs are real |
| Hard to quantify | Treated by the ratio as |
|---|---|
| Dignity in the encounter | Worth zero |
| Women’s voice and agency | Worth zero |
| Social cohesion | Worth zero |
| Ecological resilience | Worth zero |
| Institutional capacity built | Worth zero |
| CEA as a discipline of attention forces you to | Which helps even if the ratio is rough |
|---|---|
| Name the outcome you are buying | Ends vague goals |
| Cost every ingredient | Reveals hidden and donated resources |
| Name the comparator | Makes the real alternative explicit |
| State assumptions | Converts disagreement into something arguable |
| Data element | Where disputes usually arise |
|---|---|
| Cost inventory | What was left out — overheads, donated inputs, participant time |
| Effect estimate | The counterfactual, and whether it transfers |
| Comparator | Whether "nothing" or current practice was used |
| Discount rate and horizon | Whether prevention was fairly treated |
| Perspective | Whose costs were counted |
| Model discipline | Why |
|---|---|
| One assumption per labelled cell | A reviewer can change it and watch the result move |
| No hard-coded numbers in formulas | Hidden constants are the commonest source of error |
| Costs, effects and results on separate sheets | Keeps the logic followable |
| A sensitivity tab from the start | Retrofitting one means rebuilding the model |
| Every source cited in the cell comment | Provenance survives staff turnover |
| Habit | Takes |
|---|---|
| State perspective, comparator, horizon, rate | Four lines |
| Use the ingredients method | A day of inventory work |
| Report ICERs for choices between options | One extra column |
| Run and show sensitivity analysis | A spreadsheet tab |
| Present equity alongside efficiency | Disaggregating what you already have |
| Red flag | What it usually conceals |
|---|---|
| A single ratio, no range | A wide uncertainty the author would rather not show |
| An average where an ICER was needed | A poor-value upgrade presented as a bargain |
| No stated perspective | Participant costs excluded |
| One study, treated as settled | An effect estimate that has not replicated |
| A ranking with no distributional data | Efficiency gained by not reaching the hardest |
| Resource | What it offers |
|---|---|
| Drummond et al., Methods for the Economic Evaluation of Health Care Programmes | The standard textbook of the field |
| WHO-CHOICE | WHO's database and tools for comparing health interventions |
| Disease Control Priorities (DCP3) | Cost-effectiveness evidence across diseases for low/middle-income settings |
| GiveWell & the Disease Control Priorities reviews | Worked 'cost per outcome' analyses you can learn from |
| iDSI Reference Case | A shared standard for credible economic evaluation |
| Source | Best for |
|---|---|
| Drummond et al. | The standard reference; methods in full |
| WHO-CHOICE | Comparable estimates across health interventions |
| Disease Control Priorities (DCP3) | Cost-effectiveness evidence for low- and middle-income settings |
| CHEERS reporting statement | A checklist for what an analysis must disclose |
| GiveWell’s published models | Worked examples with the assumptions exposed |
| Takeaway | The mistake it prevents |
|---|---|
| Most good per rupee | Treating "cheap" as "cost-effective" |
| Match the method | Comparing a CEA ratio with a CBA one |
| Use the ICER | Justifying an upgrade with an average |
| Show the uncertainty | A point estimate read as a fact |
| Efficiency is not the only value | A ranking that quietly abandons the hardest to reach |